Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Safety and Effectiveness of LIS1 for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Peripheral T-cell Lymphoma (PTCL), which is a rare and aggressive form of non-Hodgkin lymphoma affecting the T-cells, a type of white blood cell. The study is testing a new treatment called LIS1, which is a glyco-humanized polyclonal antibody. This means it is a specially designed protein that targets and binds to specific cells in the body, in this case, the tumoral T-cells involved in PTCL. The treatment is administered as a concentrate for solution for infusion, meaning it is given directly into the bloodstream through an intravenous infusion.

The purpose of the study is to evaluate the safety and effectiveness of LIS1 in patients whose PTCL has returned or has not responded to previous treatments. The study is divided into two parts. In the first part, the focus is on determining the safest dose of LIS1 by gradually increasing the dose given to participants. This helps identify the maximum dose that can be tolerated without causing severe side effects. In the second part, the study will assess how well LIS1 works in treating PTCL by observing its effects on the cancer.

Participants in the study will receive LIS1 and will be monitored closely for any side effects and changes in their condition. The study aims to find out if LIS1 can effectively reduce the size of the tumors or slow down the progression of the disease. This research is important for developing new treatment options for patients with relapsed or refractory Peripheral T-cell Lymphoma.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be informed about the trial's objectives and procedures. The patient must provide signed, written informed consent to participate.

    The patient must meet specific health criteria, including a performance status that allows for daily activities and a life expectancy of more than three months.

  2. Step 2

    Initial assessment

    The patient will undergo an initial assessment to confirm eligibility, which includes blood tests and imaging to measure the disease.

    A bone marrow aspirate or biopsy may be required to provide a sample for central review.

  3. Step 3

    Treatment phase 1: dose escalation

    The patient will receive the medication LIS1 through an intravenous infusion. The dosage will be gradually increased to determine the maximum tolerated dose.

    Each treatment cycle lasts 28 days, during which the patient will be monitored for any side effects or adverse reactions.

  4. Step 4

    Treatment phase 2: dose expansion

    Once the appropriate dose is identified, the patient will continue to receive LIS1 at this dose to evaluate its effectiveness against the disease.

    The patient's response to the treatment will be assessed using imaging and other clinical evaluations.

  5. Step 5

    Monitoring and follow-up

    Throughout the trial, the patient will have regular check-ups to monitor health status, including blood tests and physical examinations.

    The patient will be observed for any changes in the disease and any side effects from the treatment.

  6. Step 6

    End of trial

    The trial is expected to conclude by August 2027. At the end of the trial, the patient's overall response to the treatment will be evaluated.

    The patient will receive guidance on any further treatment or follow-up care needed after the trial.

Who can join the trial?

19 criteria

  • Provide signed, written informed consent, which means you agree to participate in the study after understanding all the details.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, which indicates you are fully active or have some symptoms but can still carry out light work.
  • Have a life expectancy of more than 3 months.
  • Have adequate blood and organ function, including:
    • Hemoglobin level of at least 8.0 g/dL (blood transfusion is allowed).
    • Absolute neutrophil count (ANC) of at least 1000 cells/mm3 (without support from growth factors within 7 days of measurement).
    • Platelet count of at least 50,000 cells/mm3 (without support from growth factors or transfusion within 7 days of measurement).
    • Creatinine clearance of at least 30 mL/min, which measures kidney function.
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels less than 3 times the upper limit of normal, which are liver enzymes.
    • Serum total bilirubin less than 2 times the upper limit of normal, or less than 3 times for those with Gilbert’s Syndrome, which is a liver condition.
    • Be able to understand and sign an informed consent form.
    • Use adequate contraception during the study and for 6 months after completing therapy.
    • Be male or female and at least 18 years old at the time of giving consent.
    • For Part 1: Have a confirmed diagnosis of certain types of Peripheral T cells lymphoma (PTCL), which is a type of blood cancer, based on specific classifications.
    • Have received one or more appropriate treatments for the current disease, including specific types of chemotherapy. If you have Anaplastic Large Cell Lymphoma (ALCL), you must have received a specific drug called brentuximab vedotin or be unable to receive it due to allergy or intolerance.
    • Have experienced disease progression during or after the most recent therapy or have a disease that does not respond to treatment.
    • Have a measurable lesion, which is a tumor that can be measured by imaging tests. The longest diameter should be at least 1.5 cm for nodal lesions and more than 1 cm for extra-nodal lesions.
    • Have recovered from any side effects of previous treatments to a level that is less than Grade 1 or back to your normal state. You must not have had major surgery, chemotherapy, radiation, or biologic therapy within 2 weeks before starting the study treatment. Some exceptions may apply if the side effects do not pose a risk to you.
    • Have either unstained tissues or stained slides and a pathology report available for central review. If these are not available, a fresh tumor tissue sample is required.
    • Be able to provide a bone marrow sample no older than 3 months at screening and agree to provide another sample after treatment if needed to confirm response.

Who cannot join the trial?

4 criteria

  • Patients who have a different type of cancer than Peripheral T cells lymphoma (PTCL) cannot participate. PTCL is a type of cancer that affects certain white blood cells called T cells.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.
  • Patients who do not meet the specific health and safety requirements set by the study cannot participate. These requirements ensure the safety of participants.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

LIS1 is a glyco-humanized polyclonal antibody designed to target and attack tumoral T cells. It is being studied for its potential to treat patients with relapsed or refractory peripheral T cell lymphoma (PTCL). The trial aims to evaluate the safety and effectiveness of LIS1, determining the best dose to use in future studies.

What is already known about the treatment

LIS1 – This medication is administered as an injection and is currently being studied in clinical trials for its safety and effectiveness in treating relapsed or refractory peripheral T-cell lymphoma (PTCL). It is in the early stages of research, specifically in Phase I/II trials, and is not yet widely used in medical practice. The main therapeutic indication for LIS1 is PTCL, a type of cancer affecting the immune system. At the molecular level, LIS1 works as a glyco-humanized polyclonal antibody targeting tumoral T cells, aiming to reduce or eliminate cancerous cells. It is classified pharmacologically as an antibody therapy, focusing on enhancing the body's immune response against tumor cells.

Investigated diseases

Peripheral T-cell Lymphoma (PTCL) – Peripheral T-cell lymphoma is a group of aggressive lymphomas that originate from mature T-cells. It typically presents with symptoms such as swollen lymph nodes, fever, night sweats, and weight loss. The disease can affect various parts of the body, including the lymph nodes, liver, spleen, and skin. PTCL progresses rapidly and can spread to other organs if not managed. The exact cause of PTCL is not well understood, but it involves the abnormal growth of T-cells. It is considered a rare type of non-Hodgkin lymphoma.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-509648-88-00Protocol codeXT 23-10Estimated enrolment34 patientsSponsorXenothera

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.